Cost-effectiveness analysis of isavuconazole for the treatment of invasive aspergillosis in the Czech Republic
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Conference abstract |
| Citation | |
| Description | Over a lifetime horizon, isavuconazole yields additional 0.30 QALYs (7.80 vs. 7.50) at the additional total cost of €3059 (€18,664 vs. €15,605) compared with SoC, with the incremental cost-effectiveness ratio of €10,251 per QALY. PSA showed that probability of isavuconazole to be cost-effective is 75% at the WTP threshold. OWSA and SA confirmed the robustness of the base-case result while the most influential parameters were mortality and prevalence of mucormycosis. |